Peri-interventional endothelin-A receptor blockade improves long-term outcome in patients with ST-elevation acute myocardial infarction

Summary

Endothelin (ET)-1 is a pro-fibrotic vasoconstrictive peptide causing microvascular dysfunction and cardiac remodelling after acute ST-elevation myocardial infarction (STEMI). It acts via two distinct receptors, ET-A and ET-B, and is involved in inflammation and atherogenesis. Patients with posterior-wall STEMI were randomly assigned to intravenous BQ-123 at 400 nmol/minute (min) or placebo over 60 min, starting immediately prior to primary percutaneous coronary intervention (n=54). Peripheral blood samples were drawn at baseline as well as after 24 hours and 30 days. Myeloperoxidase (MPO), as a marker of neutrophil activation and matrix metalloproteinase 9 (MMP-9), a marker of extracellular matrix degradation were measured in plasma. Clinical follow-up was conducted by an investigator blinded to treatment allocation over three years. During the median follow-up period of 3.6 years (interquartile range [IQR] 3.3–4.1) we observed a longer event-free survival in patients randomised to receive BQ-123 compared with patients randomised to placebo (mean 4.5 years (95% confidence interval: 3.9–5) versus mean 3 years (2.2–3.7), p=0.031). Patients randomised to ET-A receptor blockade demonstrated a greater reduction of MPO levels from baseline to 24 hours compared to placebo-treated patients (-177 ng/ml (IQR 103–274) vs –108 ng/ml (74–147), p=0.006). In addition, a pronounced drop in MMP-9 levels (-568 ng/ml (44–1157) vs –117 ng/ml (57–561), p=0.018) was observed. There was no significant difference in amino-terminal propetide of pro-collagen type III levels. In conclusion, short-term administration of BQ-123 leads to a reduction in MPO, as well as MMP-9 plasma levels and to a longer event-free survival in patients with STEMI.

ClinicalTrials.gov Identifier: NCT00502528

Keywords

Acute myocardial infarction - endothelin - BQ-123 - percutaneous coronary intervention - remodelling - clinical outcome

^* CA and RW contributed equally to this work.

• References

• 1 Yanagisawa M, Kurihara H, Kimura S. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
• 2 Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol 1999; 126: 391-398.
• 3 Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851-876.
• 4 Adlbrecht C, Bonderman D, Plass C. et al. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 2007; 97: 642-649.
• 5 Lerman A, Edwards BS, Hallett JW. et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
• 6 Niccoli G, Lanza GA, Shaw S. et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006; 27: 1793-1798.
• 7 Bogoyevitch MA, Glennon PE, Andersson MB. et al. Endothelin-1 and fibrob-last growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes.The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem 1994; 269: 1110-1119.
• 8 Eitel I, Nowak M, Stehl C. et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am Heart J 2010; 159: 882-890.
• 9 Omland T, Lie RT, Aakvaag A. et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
• 10 Yip HK, Wu CJ, Chang HW. et al. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 2005; 127: 1491-1497.
• 11 Arai H, Hori S, Aramori I. et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-732.
• 12 Sakurai T, Yanagisawa M, Takuwa Y. et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-735.
• 13 Barton M, Haudenschild CC, d’Uscio LV. et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998; 95: 14367-14372.
• 14 Iwasa S, Fan J, Miyauchi T. et al. Blockade of endothelin receptors reduces dietinduced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice. Pathobiology 2001; 69: 1-10.
• 15 Carbone F, Nencioni A, Mach F. et al. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 2013; 110: 501-514.
• 16 Distelmaier K, Adlbrecht C, Jakowitsch J. et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102: 564-572.
• 17 Toffoli MC, Gabra BH, Teixeira CF. et al. Endothelins mediate neutrophil activation, ProMMP-9 release and endothelial cell detachment. Inflammation 2007; 30: 28-37.
• 18 Webb CS, Bonnema DD, Ahmed SH. et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006; 114: 1020-1027.
• 19 Kelly D, Cockerill G, Ng LL. et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007; 28: 711-718.
• 20 Ozdemir R, Parlakpinar H, Polat A. et al. Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology 2006; 219: 142-149.
• 21 Nguyen QT, Cernacek P, Calderoni A. et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98: 2323-2330.
• 22 Alberola Aguilar AM, Revert F, Moya A. et al. Intravenous BQ-123 and phosphoramidon reduce ventricular ectopic beats and myocardial infarct size in dogs submitted to coronary occlusion and reperfusion. Gen Pharmacol 2000; 35: 143-147.
• 23 Maxwell L, Harrison WR, Gavin JB. Endothelin antagonists diminish postischemic microvascular incompetence and necrosis in the heart. Microvasc Res 2000; 59: 204-212.
• 24 Adlbrecht C, Andreas M, Redwan B. et al. Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention 2012; 07: 1386-1395.
• 25 Reriani M, Raichlin E, Prasad A. et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010; 122: 958-966.
• 26 Raichlin E, Prasad A, Mathew V. et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008; 52: 522-528.
• 27 Jaovisidha P, Peeples ME, Brees AA, Carpenter LR, Moy JN. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J Immunol 1999; 163: 2816-2820.
• 28 Peake J, Wilson G, Hordern M. et al. Changes in neutrophil surface receptor expression, degranulation, and respiratory burst activity after moderate- and high-intensity exercise. Journal of applied physiology 2004; 97: 612-8.
• 29 Poulsen SH, Host NB, Jensen SE. et al. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000; 101: 1527-1532.
• 30 Spratt JC, Goddard J, Patel N. et al. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001; 134: 648-654.
• 31 Kalla K, Christ G, Karnik R. et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006; 113: 2398-2405.
• 32 Verma A, Meris A, Skali H. et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imag 2008; 01: 582-591.
• 33 Pitt B, Latini R, Maggioni AP. et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail 2011; 13: 755-764.
• 34 Lau D, Mollnau H, Eiserich JP. et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 2005; 102: 431-436.
• 35 Baldus S, Heeschen C, Meinertz T. et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445.
• 36 Brennan ML, Penn MS, Van Lente F. et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-1604.
• 37 MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol 2001; 37: 137-143.
• 38 Halcox JP, Nour KR, Zalos G, Quyyumi AA. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circulation Res 2001; 89: 969-976.
• 39 Yoon MH, Reriani M, Mario G. et al. Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol 2013; 168: 1316-1321.
• 40 Browatzki M, Pfeiffer CA, Schmidt J. et al. Endothelin-1 induces CD40 but not IL-6 in human monocytes via the proinflammatory transcription factor NFkappaB. Eur J Med Res 2005; 10: 197-201.
• 41 Babaei S, Picard P, Ravandi A. et al. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 2000; 48: 158-167.
• 42 Morand-Contant M, Anand-Srivastava MB, Couture R. Kinin B1 receptor upregulation by angiotensin II and endothelin-1 in rat vascular smooth muscle cells: receptors and mechanisms. Am J Physiol Heart Circul Physiol 2010; 299: H1625-1232.
• 43 Fraccarollo D, Hu K, Galuppo P. et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997; 96: 3963-3973.
• 44 Clozel M, Qiu C, Qiu CS. et al. Short-term endothelin receptor blockade with te-zosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 2002; 39: 142-147.
• 45 Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M. et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circulation Res 2005; 97: 125-134.
• 46 Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 1993; 27: 2125-2129.
• 47 Nguyen QT, Cernacek P, Sirois MG. et al. Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 2001; 104: 2075-2081.
• 48 Fraccarollo D, Galuppo P, Bauersachs J, Ertl G. Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 2002; 54: 559-567.
• 49 Manhenke C, Orn S, von Haehling S. et al. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol 2013; 166: 729-735.
• 50 Adlbrecht C, Wurm R, Pezawas T. et al. Effects of endothelin A receptor blockade in patients with ST-elevation acute coronary syndrome - A rhythmologic substudy. Life Sci. 2014 Epub ahead of print.